Kristie L. Kahl is vice president of content at MJH Life Sciences, overseeing CURE®, CancerNetwork®, the journal ONCOLOGY, Targeted Oncology, and Urology Times®. She has been with the company since November 2017.
She is a graduate of Rider University, where she acquired a Bachelors of Art in journalism, as well as a graduate of Temple University, where she received her Masters of Science in Sports Management.
Follow Kristie on Twitter at @KristieLKahl, or email her at email@example.com.
As stereotactic ablative radiation therapy enters further into the treatment space for metastatic RCC, integration of the approach is vital for physicians to focus on, according to Raquibul Hannan, MD, PhD.
Compared with data from the KEYNOTE-057 study, the use of pembrolizumab monotherapy in the real-world setting was similar in the treatment of patients with high-risk non-muscle invasive bladder cancer.
The combination use of PSMA-targeted radionuclide therapy tailored by the individual patient and dose may show promise in the future treatment of men with metastatic castration-resistant prostate cancer.